Takeda’s phase 2b study of Mezagitamab shows potential to transform treatment of primary immune…
Takeda Plans to Initiate Global Phase 3 Trial of Mezagitamab in ITP in the Second Half of FY2024
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.